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A B S T R A C T
We report a rare case of C. krusei knee arthritis treated with instillation of micafungin and arthroscopy. A 49-
year-old man hospitalized for treatment of Acute Myeloid Leukemia developed knee arthritis with C. krusei. He
was treated with a combination of arthroscopic debridement, intravenous as well as intra-articular micafungin.
Serum and intra-articular concentrations of micafungin were determined. After instillation of micafungin in the
knee and arthroscopic debridement, the patient completely recovered.
1. Introduction
In the Netherlands, septic arthritis is a relatively rare disease with
an incidence of 5,7 per 100.000 inhabitants per year [1], and in adults
mostly aﬀects the knee [2].
Urgent treatment of septic arthritis is necessary to prevent further
irreversible joint destruction. In humans with intact immunity most
septic arthritis are bacterial and caused by S. aureus [3]. In im-
munocompromised patients, Candida species can infrequently be the
cause of an infectious arthritis as well [4]. As the number of patients
with malignant hematological diseases that are receiving treatments
with new immunotherapies and molecular targeted agents is increasing
rapidly, more patients are at risk for invasive fungal infections [5]. The
treatment of a septic arthritis caused by Candida is not well deﬁned,
although a successful outcome has been reported with oral or in-
travenous antifungal therapy with ﬂuconazole, amphotericin-B and
voriconazole [6–8].
However, few data are available about the pharmacokinetics of
antifungal agents in synovial ﬂuid and tissue and it is unclear if the
achieved concentrations exceed the minimal inhibitory concentration
(MIC) of Candida species. To attempt to achieve appropriate articular
drug concentrations, instillation of amphotericin-B into the joint has
been used as adjuvant therapy as well [9,10].
Recent guidelines on the treatment of invasive Candida infections
recommend the use of ﬂuconazole, an echinocandin or liposomal am-
photericin-B for Candida arthritis [11]. In case of a ﬂuconazole resistant
Candida species like C. krusei an echinocandin or liposomal ampho-
tericin-B are the only appropriate initial antifungal therapies available.
To the best of our knowledge, intra-articular instillation of micafungin
to treat a septic arthritis with Candida species has not been described.
Here we report a case of knee arthritis with C. krusei treated with a
combination of surgical debridement, intravenous as well as intra-ar-
ticular micafungin.
2. Case
A previously healthy 49-year-old man who developed Acute
Myeloid Leukemia (AML), was admitted to the Hematology department
to initiate intensive remission-induction chemotherapy. During the
subsequent chemotherapy-induced episode of febrile neutropenia his
blood cultures became positive for C. krusei. Treatment with in-
travenous micafungin 100mg once daily was initiated. Prophylaxis with
ﬂuconazole was stopped and his central venous line was removed. C.
krusei was also cultured from a weekly surveillance rectal swab culture
and therefore, the most likely source of the candidemia was gastro-
intestinal translocation. After his blood cultures became negative, in-
travenous micafungin was continued for another 2 weeks and he could
be discharged.
A week later, the patient was readmitted for a second course of
chemotherapy and amphotericin-B oral solution was given to prevent a
new episode of translocation of C. krusei. During this hospital stay he hit
his left knee on the side of the bed. His knee continued to be painful and
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as a knee eﬀusion was noted three days after injury, the orthopedic
surgeon was consulted. On physical examination a large eﬀusion of his
left knee was found. The joint was not visibly red, but was warm on
palpation. His temperature was 38.4° Celsius. A plain knee radiograph
of the knee was normal. An aspiration of the aﬀected knee was per-
formed and the joint ﬂuid was sent for culture, this day was considered
as day 0. Day 1 the joint aspiration grew C. krusei for which intravenous
micafungin was restarted at a dose of 100mg twice daily. As the patient
was deeply thrombopenic as well as neutropenic at that time, no ar-
throscopic drainage and lavage was performed but instead the knee was
repeatedly drained by needle aspiration. On the day of the ﬁrst needle
aspiration of the knee and for the next 10 days, blood cultures were
positive for C. krusei as well. Furthermore, repeated needle aspirations
of the knee continued to grow C. krusei. An echocardiography at day 6
was normal. The ongoing candidemia and repeatedly positive synovial
ﬂuid cultures led to the decision at day 7 to instill micafungin in the
knee at a dose of 1mg in 10ml saline. Furthermore, liposomal ampho-
tericin-B was started at day 8 at 3mg/kg/day intravenously while in-
travenous micafungin was continued. After 4 days intra-articular in-
jections were stopped. However, despite repopulation from
chemotherapy induced neutropenia, his blood cultures as well as sy-
novial ﬂuid cultures continued to be positive. At day 13 a whole-body
PET scan showed arthritis of the left knee, PET positive pulmonary
inﬁltrates, and some pleural ﬂuid. Since the patients was no longer
cytopenic the decision was made at day 17 to perform an arthroscopic
debridement and lavage of the knee with an extensive arthroscopic
synovectomy. Furthermore, the intra-articular administration of mica-
fungin was reinitiated and continued for 7 days with at a dose of 3 mg
per instillation (as a solution of 1mg in 10ml sodium chloride 0.9%).
From this point onwards his blood cultures remained negative and he
improved clinically. Further follow-up of his left knee revealed good
recovery with less pain and good function six months postoperative.
C. krusei has been identiﬁed with the use of CHROMagar™ with
subsequent identiﬁcation by Maldi-TOF, with database MALDI BDAL
Database version 8.0. Micafungin concentrations were measured (la-
boratory of pharmacy, University Hospital Nijmegen, the Netherlands)
in serum and joint ﬂuid [12]. The concentrations in serum 12 hours
after the administration of 100mg intravenously at day 13 and 16 of
therapy were 4.5 and 1.5mg/L respectively and concentration in sy-
novial ﬂuid 24 hours after installation of 3mg of micafungin in the knee
was 11mg/L at day 19, as well presented in Table 1. Reference con-
centrations of micafungin in serum derived from 2 studies in critically
ill patients trough level 1.4–3.1 mg/L were described [12,13]. In
healthy subjects, micafungin has as a volume of distribution of 0,2L/kg
with a half-life of 15 hours. Administration of 100mg once daily results
in trough serum concentration levels of 2 mg-L [14]. In hematology
patients reference concentrations after intravenous micafungin are
available as well [15].
3. Discussion
We present a rare case of knee arthritis caused by C. krusei during
chemotherapy induced neutropenia in a patient with AML. He was
successfully treated with a combination of surgical debridement, in-
travenous as well as intra-articular micafungin.
Micafungin is an echinocandin, registered for the treatment of
Candida infections. Despite intravenous therapy with micafungin and
repeated needle aspiration of the knee, blood as well as synovial ﬂuid
cultures continued to be positive in our patient. Eventually, the com-
bination of surgical debridement and the intra-articular instillation of
micafungin led to clinical resolution of the infection.
Patients undergoing intensive chemotherapy for hematological
malignancies often receive prophylaxis against invasive Candida in-
fections with ﬂuconazole. However, breakthrough candidemia with
ﬂuconazole resistant candida species, like C. krusei are occasionally
observed [16]. In these patients, Candida arthritis is typically the
consequence of hematogenic dissemination [6].
Lu et al. presented a case report of knee arthritis with C. krusei and
reviewed the available literature on 4 other cases [17]. Given the 30-
year time frame of these 5 cases, it is not surprising that the antifungal
therapy given to these patients was diverse and only 2 received an
echinocandin. Our patient was treated with surgical debridement in
combination with intravenous and intra-articular micafungin for a total
of 12 days.
Synovial ﬂuid is a transudate of plasma, so dissolution of mica-
fungin in synovial ﬂuid will be likely. Moreover, diﬀusion from plasma
to the synovial ﬂuid will occur. Unfortunately, data about the extent of
diﬀusion from plasma to the synovial ﬂuid are not available. The pos-
sible side eﬀects as well as the possible toxic eﬀects on cartilage of
micafungin when administered directly into a joint are unknown.
However, we decided to administer micafungin through direct intra-
articular instillation as, despite prolonged high-dose intravenous mi-
cafungin therapy, blood as well as synovial cultures remained positive
in our patient. Reconstitution of micafungin in NaCl 0.9% results in a
pH of 5–7 [18]. Further dissolution in NaCl 0.9% will results in a pH of
about 7, with isotonic properties. A dose of 3mg per instillation was
given from day 17–24 as a 1mg/10ml NaCl 0.9% solution. This dose
was anticipated to result in local concentrations well above the MIC of
the C. krusei (0.125 μg/ml) for a suﬃciently long time and this was
conﬁrmed by the measured micafungin concentration in synovial ﬂuid
of 11mg/l 24 hours after instillation, a concentration several times
higher than what was measured in blood in the same patient (Table 1).
Toxicity of the joint is one of the main concerns after local injection.
Despite the high local concentration of 11mg/l, no local toxicity was
observed as the patient recovered with minor complaints of his knee.
Besides anti-bacterial or anti-fungal medication, load reduction is
key in patients with septic arthritis and can be performed by arthro-
scopy or arthrotomy. Arthroscopic treatment is preferable to ar-
throtomy in terms of pain, rehabilitation and range of motion [19].
Surgical irrigation and debridement is not always needed in mild dis-
ease burden, although the literature is lacking on this and consists of
case reports [6].
In conclusion, instillation of micafungin in the knee of a patient with
therapy resistant C. krusei arthritis led to therapeutic synovial con-
centrations and was used successfully in combination with surgical
debridement.
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Table 1
Administration of micafungin and micafungin concentrations over time.
Day of administration
micafungin
Route of
administration
Dose Micafungin
concentration (mg/L)
day 1 – day 15 IV 100mg
BID
day 7 – day 10 IA 3–10 –
20–20 mg
day 14 4.5 (trough serum)
day 16 – day 32 IV 200mg OD
day 17b 1.5 (trough serum)
day 17 – day 24 IA 3mg OD
day 19 11 (joint)a
Abbreviations: IA: intra-articular, IV: intravenous, BID: two times daily, OD:
one time daily.
a Aspiration of joint ﬂuid 24 hours after administration of micafungin
(trough concentration).
b Day of surgery.
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